8-KEarnings & ResultsExhibits & Filings

AbbVie Inc. 8-K Report, Financial Results (Apr 26, 2013)

Filed April 26, 2013For Securities:ABBV

Summary

AbbVie Inc. (ABBV) filed an 8-K report on April 26, 2013, primarily to announce its first-quarter 2013 financial results. This filing includes a press release detailing the company's performance for the period. Investors should note that this report serves as the official dissemination of AbbVie's Q1 2013 earnings, providing key financial metrics and operational updates. While the 8-K itself is largely procedural, the furnished press release (Exhibit 99.1) is the critical document for understanding AbbVie's financial health and outlook following its spin-off from Abbott Laboratories in January 2013. Investors would look to this press release for details on revenue, earnings per share, and potentially segment performance, especially concerning its flagship product Humira, and any forward-looking guidance provided by management.

Key Highlights

  • 1AbbVie Inc. filed an 8-K report on April 26, 2013.
  • 2The primary purpose of the filing is to report financial results and condition.
  • 3Specifically, the report announces AbbVie's results of operations for the first quarter of 2013.
  • 4A press release detailing these Q1 2013 results is furnished as Exhibit 99.1.
  • 5The press release is incorporated by reference into the 8-K filing.
  • 6William J. Chase, Executive Vice President and Chief Financial Officer, signed the report.
  • 7This filing provides investors with the official disclosure of AbbVie's initial quarterly performance as an independent company.

Frequently Asked Questions

The main purpose of this 8-K filing from AbbVie Inc. on April 26, 2013, is to officially announce and provide the company's financial results for the first quarter of 2013. This includes furnishing the press release that contains the detailed earnings report.

The actual financial results for AbbVie's first quarter of 2013 are contained within the press release, which is provided as Exhibit 99.1 to this 8-K filing. Investors should refer to this exhibit for detailed financial information and commentary.

Yes, AbbVie Inc. was spun off from Abbott Laboratories effective January 1, 2013. This 8-K filing represents one of AbbVie's earliest official financial disclosures as an independent, publicly traded company, reporting on its first quarter of operations post-separation.

The 8-K report was signed by William J. Chase, who held the position of Executive Vice President and Chief Financial Officer of AbbVie Inc. at the time of the filing.